These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 29948964)

  • 1. Economic Evaluation for USA of Systemic Chemotherapies as First-Line Treatment of Metastatic Pancreatic Cancer.
    Gharaibeh M; McBride A; Alberts DS; Slack M; Erstad B; Alsaid N; Bootman JL; Abraham I
    Pharmacoeconomics; 2018 Oct; 36(10):1273-1284. PubMed ID: 29948964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Paclitaxel as Albumin-Bound Nanoparticles with Gemcitabine for Untreated Metastatic Pancreatic Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Stainthorpe A; Greenhalgh J; Bagust A; Richardson M; Boland A; Beale S; Duarte R; Kotas E; Banks L; Palmer D
    Pharmacoeconomics; 2018 Oct; 36(10):1153-1163. PubMed ID: 29600384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic Evaluation for the UK of Systemic Chemotherapies as First-Line Treatment of Metastatic Pancreatic Cancer.
    Gharaibeh M; McBride A; Alberts DS; Erstad B; Slack M; Alsaid N; Bootman JL; Abraham I
    Pharmacoeconomics; 2018 Nov; 36(11):1333-1343. PubMed ID: 29981004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic evaluation for the US of nab-paclitaxel plus gemcitabine versus FOLFIRINOX versus gemcitabine in the treatment of metastatic pancreas cancer.
    Gharaibeh M; McBride A; Bootman JL; Patel H; Abraham I
    J Med Econ; 2017 Apr; 20(4):345-352. PubMed ID: 27919186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic evaluation for the UK of nab-paclitaxel plus gemcitabine in the treatment of metastatic pancreas cancer.
    Gharaibeh M; McBride A; Bootman JL; Abraham I
    Br J Cancer; 2015 Apr; 112(8):1301-5. PubMed ID: 25791875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis of FOLFIRINOX vs gemcitabine with nab-paclitaxel as adjuvant treatment for resected pancreatic cancer in the United States based on PRODIGE-24 and APACT trials.
    Kharat AA; Nelson R; Au T; Biskupiak J
    J Manag Care Spec Pharm; 2021 Oct; 27(10):1367-1375. PubMed ID: 34595948
    [No Abstract]   [Full Text] [Related]  

  • 7. Cost-effectiveness analysis of nab-paclitaxel plus gemcitabine versus folfirinox in the treatment of metastatic pancreatic cancer in china.
    Cui J; Zhang X; Qu S; Wang L
    Expert Rev Pharmacoecon Outcomes Res; 2021 Aug; 21(4):691-697. PubMed ID: 32976031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-World Cost-Effectiveness of First-Line Gemcitabine Plus Nab-Paclitaxel vs FOLFIRINOX in Patients With Advanced Pancreatic Cancer.
    Arciero V; Luo J; Parmar A; Dai WF; Beca JM; Raphael MJ; Isaranuwatchai W; Habbous S; Tadrous M; Earle CC; Biagi JJ; Mittmann N; Arias J; Gavura S; Chan KKW
    JNCI Cancer Spectr; 2022 Jul; 6(4):. PubMed ID: 35758620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness analysis of treatments for metastatic pancreatic cancer based on PRODIGE and MPACT trials.
    Zhou J; Zhao R; Wen F; Zhang P; Wu Y; Tang R; Chen H; Zhang J; Li Q
    Tumori; 2016 Jun; 2016(3):294-300. PubMed ID: 27056335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinical effectiveness and cost-effectiveness of gemcitabine for metastatic breast cancer: a systematic review and economic evaluation.
    Takeda AL; Jones J; Loveman E; Tan SC; Clegg AJ
    Health Technol Assess; 2007 May; 11(19):iii, ix-xi, 1-62. PubMed ID: 17462169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-utility analysis of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in combination with gemcitabine in metastatic pancreatic cancer in Spain: results of the PANCOSTABRAX study.
    Carrato A; García P; López R; Macarulla T; Rivera F; Sastre J; Gostkorzewicz J; Benedit P; Pérez-Alcántara F
    Expert Rev Pharmacoecon Outcomes Res; 2015; 15(4):579-89. PubMed ID: 25991037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Value of Survival Gains in Pancreatic Cancer from Novel Treatment Regimens.
    MacEwan JP; Yin W; Kaura S; Khan ZM
    J Manag Care Spec Pharm; 2017 Feb; 23(2):206-213. PubMed ID: 28125374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-Effectiveness Analysis of Systemic Therapies in Advanced Pancreatic Cancer in the Canadian Health Care System.
    Coyle D; Ko YJ; Coyle K; Saluja R; Shah K; Lien K; Lam H; Chan KK
    Value Health; 2017 Apr; 20(4):586-592. PubMed ID: 28408000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic Evaluation of Cisplatin Plus Gemcitabine Versus Paclitaxel Plus Gemcitabine for the Treatment of First-Line Advanced Metastatic Triple-Negative Breast Cancer in China: Using Markov Model and Partitioned Survival Model.
    Rui M; Shi F; Shang Y; Meng R; Li H
    Adv Ther; 2020 Sep; 37(9):3761-3774. PubMed ID: 32647912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-Effectiveness of Nab-Paclitaxel and Gemcitabine Versus Gemcitabine Monotherapy for Patients with Unresectable Metastatic Pancreatic Cancer in Japan.
    Morimoto K; Moriwaki K; Kaneyasu T; Nakayama H; Shimozuma K
    Value Health Reg Issues; 2022 Mar; 28():54-60. PubMed ID: 34800832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
    Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N
    Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) + gemcitabine vs gemcitabine alone for metastatic pancreatic cancer patients: the APICE study.
    Lazzaro C; Barone C; Caprioni F; Cascinu S; Falcone A; Maiello E; Milella M; Pinto C; Reni M; Tortora G
    Expert Rev Pharmacoecon Outcomes Res; 2018 Aug; 18(4):435-446. PubMed ID: 29641931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of Gemcitabine Plus Modern Radiotherapy in Locally Advanced Pancreatic Cancer.
    Leung HW; Chan AL; Muo CH
    Clin Ther; 2016 May; 38(5):1174-83. PubMed ID: 27033672
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The clinical and cost-effectiveness of oxaliplatin and capecitabine for the adjuvant treatment of colon cancer: systematic review and economic evaluation.
    Pandor A; Eggington S; Paisley S; Tappenden P; Sutcliffe P
    Health Technol Assess; 2006 Nov; 10(41):iii-iv, xi-xiv, 1-185. PubMed ID: 17049138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Using economic analysis to evaluate the potential of multimodality therapy for elderly patients with locally advanced pancreatic cancer.
    Krzyzanowska MK; Earle CC; Kuntz KM; Weeks JC
    Int J Radiat Oncol Biol Phys; 2007 Jan; 67(1):211-8. PubMed ID: 17189071
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.